Skip to main content
  • Register
  • Help
  • Contact us

Allergy Therapeutics Plc (AGY) Ord GBP0.01

Sell:21.20p Buy:22.00p 0 Change: No change
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:21.20p
Buy:22.00p
Change: No change
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:21.20p
Buy:22.00p
Change: No change
Market closed Prices as at close on 7 May 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

Contact details

Address:
Dominion Way
WORTHING
BN14 8SA
United Kingdom
Telephone:
+44 (01903) 844700
Website:
www.allergytherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 03 March 2021 03/03/21
Final results 03 March 2021 03/03/21
Trading Announcement 13 January 2021 13/01/21
AGM 08 December 2020 08/12/20
Annual report 10 November 2020 10/11/20
Final results 23 September 2020 23/09/20
Trading Announcement 15 July 2020 15/07/20
Trading Announcement 24 June 2020 24/06/20

General stock information

EPIC:
AGY
ISIN:
GB00B02LCQ05
Market cap:
£138.56 million
Shares in issue:
641.48 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Manuel Llobet
    Chief Executive Officer, Executive Director
  • Nicolas Wykeman
    Chief Financial Officer, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.